Larazotide acetate
Investigational — celiac adjunct peptide — not approved.
What it's for
Investigational — celiac adjunct peptide — not approved.
What it's for
Larazotide acetate is an still being studied oral peptide that gently adjusts intestinal tight junctions.
What it does for the body
It has been studied as an adjunct to gluten-free diet in celiac disease to reduce symptoms from inadvertent gluten exposure. Not approved. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
It antagonizes zonulin-mediated tight-junction opening, aiming to reduce between-cell (paracellular) gluten peptide passage. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Larazotide acetate is still being studied in people. Watch for peer-reviewed trial readouts and regulator decisions — not just social-media summaries.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Larazotide acetate — FDA.gov search
- ClinicalTrials.gov search: Larazotide acetate — U.S. clinical trials registry
- Drugs@FDA search: Larazotide acetate — FDA drug database (if approved)
- PubMed search: Larazotide acetate — NCBI PubMed
- PubMed Central search: Larazotide acetate — NCBI PMC